The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Afamelanotide (Brand name: Scenesse)
- Manufactured by
FDA-approved indication: October 2019, afamelanotide (Scenesse) was approved to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).
National Library of Medicine Drug Information Portal